FIELD: biotechnology.
SUBSTANCE: invention can be used in medicine to treat a disease mediated by activation of an alternative complement pathway. A polypeptide consisting of hfB3-292S (amino acids 1-764 or 26-764 in SEQ ID NO: 2), hfB3-292SN480 (amino acids 1-480 or 26-480 in SEQ ID NO: 2) or hfB3-292S-Fc (amino acids 1-990 or 26-990 in SEQ ID NO: 22) is obtained.
EFFECT: invention allows to effectively inhibit the activity of the alternative complement pathway when using the resulting polypeptide, coding its nucleic acid or expression vector.
12 cl, 14 dwg, 6 tbl, 19 ex
Title |
Year |
Author |
Number |
AFFINITY-MATURED CRIG VERSIONS |
2009 |
- Sidkhu, Sachdev, S.
- Li, Bin
- Van Lokeren Kampagne, Menno
- Vismann, Kristian
|
RU2553517C2 |
COMPOSITIONS AND METHODS OF INHIBITING MASP-1, MASP-2 AND/OR MASP-3 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA |
2013 |
- Shveble Khans-Vilkhelm
- Demopulos Gregori A.
|
RU2655299C2 |
C3b ANTIBODIES AND METHODS FOR PREVENTION AND TREATMENT OF COMPLEMENT-RELATED DISORDERS |
2008 |
- Van Lokeren Kampagne Menno
|
RU2473563C2 |
ANTIBODIES AGAINST FACTOR D AND THEIR USE |
2018 |
- Song, Wenchao
- Zhou, Lin
- Sato, Sayaka
- Miwa, Takashi
- Gullipalli, Damodar
- Golla, Madhu
|
RU2799044C2 |
CODON-OPTIMIZED COMPLEMENT FACTOR I |
2019 |
- Joel Josephine Heather Lucienne
|
RU2824048C2 |
COMPLEMENT FACTOR I AND COMPLEMENT FACTOR I COFACTOR, VECTORS ENCODING THEM AND USE FOR THERAPEUTIC PURPOSES |
2019 |
- Dreismann Anna
- Ellis Scott
- Joel Josephine Heather Lucienne
|
RU2809247C2 |
HUMANIZED ANTIBODIES TO COMPLEMENT FACTOR BB AND USE THEREOF |
2021 |
- Parry, Graham
- Moore, Stephen
- Storek, Michael
- Leksa, Nina, C.
|
RU2840491C1 |
OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF EYE DISEASES |
2018 |
- Femili, Amin
- Fukh, Dzhermen
- Kenig, Patrik
- Li, Chingvej, Vivan
- Radzhagopal, Kartikan
|
RU2782355C2 |
ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION |
2007 |
- Grinberg, Asja
- Nopf, Dzhon
- Kumar, Ravindra
- Pirsall, Robert, Skott
- Sikhra, Dzhasbir
|
RU2559532C2 |
ISOLATED GLYCOPROTEIN IB ALPHA POLYPEPTIDE OF HUMAN THROMBOCYTES, FUSED PROTEIN, DNA MOLECULE (VERSIONS), EXPRESSION VECTOR (VERSIONS), CELL (VERSIONS), POLYPEPTIDE EXPRESSION METHOD, FUSED PROTEIN EXPRESSION METHOD, PHARMACEUTICAL COMPOSITION (VERSIONS), METHOD OF INHIBITING BODING OF BLOOD CELLS TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM, METHOD OF INHIBITING BONDING OF PROTEIN TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM AND DISORDER TREATMENT METHOD |
2004 |
- Sho Grej
- Sako Dajann S.
- Kumar Ravindra
- Sjuj Tszin'
|
RU2403262C2 |